JP2019512498A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512498A5 JP2019512498A5 JP2018548393A JP2018548393A JP2019512498A5 JP 2019512498 A5 JP2019512498 A5 JP 2019512498A5 JP 2018548393 A JP2018548393 A JP 2018548393A JP 2018548393 A JP2018548393 A JP 2018548393A JP 2019512498 A5 JP2019512498 A5 JP 2019512498A5
- Authority
- JP
- Japan
- Prior art keywords
- antisense oligonucleotide
- pharmaceutical composition
- composition according
- conjugate
- oligonucleotide conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16160149.7 | 2016-03-14 | ||
| EP16160149 | 2016-03-14 | ||
| PCT/EP2017/055925 WO2017157899A1 (en) | 2016-03-14 | 2017-03-14 | Oligonucleotides for reduction of pd-l1 expression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020106728A Division JP7002603B2 (ja) | 2016-03-14 | 2020-06-22 | Ｐｄ－ｌ１発現低減用のオリゴヌクレオチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019512498A JP2019512498A (ja) | 2019-05-16 |
| JP2019512498A5 true JP2019512498A5 (enExample) | 2020-04-16 |
| JP6748219B2 JP6748219B2 (ja) | 2020-08-26 |
Family
ID=58314191
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018548393A Active JP6748219B2 (ja) | 2016-03-14 | 2017-03-14 | Ｐｄ−ｌ１発現低減用のオリゴヌクレオチド |
| JP2020106728A Active JP7002603B2 (ja) | 2016-03-14 | 2020-06-22 | Ｐｄ－ｌ１発現低減用のオリゴヌクレオチド |
| JP2021212541A Active JP7447073B2 (ja) | 2016-03-14 | 2021-12-27 | Ｐｄ－ｌ１発現低減用のオリゴヌクレオチド |
| JP2024000251A Active JP7791222B2 (ja) | 2016-03-14 | 2024-01-04 | Ｐｄ－ｌ１発現低減用のオリゴヌクレオチド |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020106728A Active JP7002603B2 (ja) | 2016-03-14 | 2020-06-22 | Ｐｄ－ｌ１発現低減用のオリゴヌクレオチド |
| JP2021212541A Active JP7447073B2 (ja) | 2016-03-14 | 2021-12-27 | Ｐｄ－ｌ１発現低減用のオリゴヌクレオチド |
| JP2024000251A Active JP7791222B2 (ja) | 2016-03-14 | 2024-01-04 | Ｐｄ－ｌ１発現低減用のオリゴヌクレオチド |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US20170283496A1 (enExample) |
| EP (2) | EP3430141B1 (enExample) |
| JP (4) | JP6748219B2 (enExample) |
| KR (5) | KR102580776B1 (enExample) |
| CN (5) | CN114717235A (enExample) |
| AR (2) | AR108038A1 (enExample) |
| AU (4) | AU2017235278C1 (enExample) |
| CA (2) | CA3120687A1 (enExample) |
| CL (4) | CL2018002570A1 (enExample) |
| CO (1) | CO2018007761A2 (enExample) |
| CR (2) | CR20180432A (enExample) |
| DK (1) | DK3430141T3 (enExample) |
| ES (1) | ES2857702T3 (enExample) |
| HR (1) | HRP20210315T1 (enExample) |
| HU (1) | HUE053172T2 (enExample) |
| IL (5) | IL303077B2 (enExample) |
| LT (1) | LT3430141T (enExample) |
| MX (2) | MX2018010830A (enExample) |
| MY (1) | MY194912A (enExample) |
| PE (3) | PE20181892A1 (enExample) |
| PH (1) | PH12018501964A1 (enExample) |
| PL (1) | PL3430141T3 (enExample) |
| PT (1) | PT3430141T (enExample) |
| RS (1) | RS61528B1 (enExample) |
| RU (1) | RU2747822C2 (enExample) |
| SG (1) | SG11201807854SA (enExample) |
| SI (1) | SI3430141T1 (enExample) |
| TW (5) | TWI840950B (enExample) |
| UA (1) | UA127432C2 (enExample) |
| WO (1) | WO2017157899A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9394333B2 (en) | 2008-12-02 | 2016-07-19 | Wave Life Sciences Japan | Method for the synthesis of phosphorus atom modified nucleic acids |
| MX342945B (es) | 2009-07-06 | 2016-10-18 | Ontorii Inc * | Profármacos de ácido nucleico novedosos y métodos de uso de los mismos. |
| DK2620428T3 (da) | 2010-09-24 | 2019-07-01 | Wave Life Sciences Ltd | Asymmetrisk hjælpegruppe |
| US9605019B2 (en) | 2011-07-19 | 2017-03-28 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
| KR20240148947A (ko) | 2012-07-13 | 2024-10-11 | 웨이브 라이프 사이언시스 리미티드 | 키랄 제어 |
| SG11201500239VA (en) | 2012-07-13 | 2015-03-30 | Wave Life Sciences Japan | Asymmetric auxiliary group |
| WO2015108048A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| WO2015108047A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
| ES2917473T3 (es) | 2014-01-16 | 2022-07-08 | Wave Life Sciences Ltd | Diseño quiral |
| JP2018520688A (ja) | 2015-07-21 | 2018-08-02 | ザ チルドレンズ メディカル センター コーポレーション | Ｐｄ−ｌ１発現造血幹細胞およびその使用 |
| TWI840950B (zh) | 2016-03-14 | 2024-05-01 | 瑞士商赫孚孟拉羅股份公司 | 用於降低pd-l1表現之寡核苷酸 |
| CN109477103A (zh) | 2016-06-22 | 2019-03-15 | ProQR治疗上市公司Ⅱ | 单链rna-编辑寡核苷酸 |
| EP3494219A1 (en) * | 2016-08-03 | 2019-06-12 | Aalborg Universitet | ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS |
| EP3507366B1 (en) | 2016-09-01 | 2020-10-07 | ProQR Therapeutics II B.V. | Chemically modified single-stranded rna-editing oligonucleotides |
| EP3523434A1 (en) | 2016-10-07 | 2019-08-14 | Secarna Pharmaceuticals GmbH & Co. KG | Novel approach for treating cancer |
| US11879137B2 (en) | 2017-09-22 | 2024-01-23 | The Children's Medical Center Corporation | Treatment of type 1 diabetes and autoimmune diseases or disorders |
| TW202424191A (zh) * | 2017-10-16 | 2024-06-16 | 瑞士商赫孚孟拉羅股份公司 | 用於降低PAPD5及PAPD7 mRNA以治療B型肝炎感染之核酸分子 |
| MY201698A (en) | 2017-10-20 | 2024-03-13 | Dicerna Pharmaceuticals Inc | Methods for treating hepatitis b infection |
| EA202091693A1 (ru) * | 2018-01-12 | 2021-04-14 | Бристол-Маерс Сквибб Компани | Антисмысловые олигонуклеотиды, целенаправленно воздействующие на альфа-синуклеин, и их применения |
| MX2020007433A (es) | 2018-01-12 | 2020-09-14 | Bristol Myers Squibb Co | Oligonucleotidos antisentido que actuan sobre alfa-sinucleina, y usos de estos. |
| GB201808146D0 (en) | 2018-05-18 | 2018-07-11 | Proqr Therapeutics Ii Bv | Stereospecific Linkages in RNA Editing Oligonucleotides |
| MX2020013930A (es) | 2018-06-22 | 2021-03-09 | Hoffmann La Roche | Oligonucleotidos para modular la expresion del canal de sodio dependiente de voltaje alfa subunidad 9 (scn9a). |
| WO2020007772A1 (en) * | 2018-07-02 | 2020-01-09 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting gbp-1 |
| WO2020011653A1 (en) * | 2018-07-09 | 2020-01-16 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting kynu |
| BR112021000538A2 (pt) | 2018-07-13 | 2021-04-06 | F. Hoffmann-La Roche Ag | Oligonucleotídeos para modular a expressão de rtel1 |
| US20210380978A1 (en) * | 2018-10-15 | 2021-12-09 | The Brigham And Women`S Hospital, Inc. | The long non-coding RNA INCA1 and Homo sapiens heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) as therapeutic targets for immunotherapy |
| WO2020178258A1 (en) * | 2019-03-05 | 2020-09-10 | F. Hoffmann-La Roche Ag | Intracellular targeting of molecules |
| US20220177894A1 (en) | 2019-04-02 | 2022-06-09 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for immunotherapy |
| KR20220019676A (ko) * | 2019-04-26 | 2022-02-17 | 스톡 테라퓨틱스, 인크. | 선택적 인트론의 스플라이싱을 조절하기 위한 방법 및 조성물 |
| US20220220485A1 (en) * | 2019-05-03 | 2022-07-14 | Secarna Pharmaceuticals Gmbh & Co. Kg | PD-L1 antisense oligonucleotides for use in tumor treatment |
| CN114829601A (zh) * | 2019-12-19 | 2022-07-29 | 豪夫迈·罗氏有限公司 | Sbds抑制剂用于治疗乙型肝炎病毒感染的用途 |
| JP7634542B2 (ja) * | 2019-12-19 | 2025-02-21 | エフ． ホフマン－ラ ロシュ アーゲー | Ｂ型肝炎ウイルス感染症を処置するためのｓｅｐｔ９阻害剤の使用 |
| US20210214727A1 (en) * | 2019-12-20 | 2021-07-15 | Hoffmann-La Roche Inc. | Enhanced oligonucleotides for inhibiting scn9a expression |
| EP4081217A1 (en) * | 2019-12-24 | 2022-11-02 | F. Hoffmann-La Roche AG | Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv |
| WO2021173812A1 (en) * | 2020-02-28 | 2021-09-02 | Aligos Therapeutics, Inc. | Methods and compositions for targeting pd-l1 |
| JP2023536999A (ja) * | 2020-08-05 | 2023-08-30 | エフ． ホフマン－ラ ロシュ アーゲー | Ｂ型肝炎患者のオリゴヌクレオチド処置 |
| CN114507663A (zh) * | 2020-11-16 | 2022-05-17 | 浙江柏拉阿图医药科技有限公司 | 寡核苷酸及其在抗乙型肝炎和丁型肝炎病毒中的应用 |
| TW202246500A (zh) * | 2021-02-02 | 2022-12-01 | 瑞士商赫孚孟拉羅股份公司 | 用於抑制 ｒｔｅｌ１ 表現之增強型寡核苷酸 |
| CN115216474B (zh) * | 2021-04-15 | 2025-09-30 | 武汉大学 | 促进pd-l1外显子3跳跃的反义寡核苷酸及其应用 |
| WO2023011597A1 (en) * | 2021-08-04 | 2023-02-09 | Hepagene Therapeutics (HK) Limited | Ligand conjugates for delivery of therapeutically active agents |
| CN113789324B (zh) * | 2021-08-17 | 2023-08-25 | 广东省大湾区华南理工大学聚集诱导发光高等研究院 | 一种aie探针及其制备方法与在荧光定量pcr方法中的应用 |
| IL312635A (en) | 2021-11-11 | 2024-07-01 | Hoffmann La Roche | Pharmaceutical combinations for treatment of hbv |
| CA3257440A1 (en) * | 2022-07-06 | 2024-01-11 | Adverum Biotechnologies, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACHROMOTOPSY |
| CN121488037A (zh) * | 2023-07-20 | 2026-02-06 | 上海舶望制药有限公司 | 用于抑制pd-l1表达的组合物和方法 |
Family Cites Families (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5927900A (ja) | 1982-08-09 | 1984-02-14 | Wakunaga Seiyaku Kk | 固定化オリゴヌクレオチド |
| US4948882A (en) | 1983-02-22 | 1990-08-14 | Syngene, Inc. | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis |
| US4587044A (en) | 1983-09-01 | 1986-05-06 | The Johns Hopkins University | Linkage of proteins to nucleic acids |
| US5430136A (en) | 1984-10-16 | 1995-07-04 | Chiron Corporation | Oligonucleotides having selectably cleavable and/or abasic sites |
| US5525465A (en) | 1987-10-28 | 1996-06-11 | Howard Florey Institute Of Experimental Physiology And Medicine | Oligonucleotide-polyamide conjugates and methods of production and applications of the same |
| DE3738460A1 (de) | 1987-11-12 | 1989-05-24 | Max Planck Gesellschaft | Modifizierte oligonukleotide |
| US5391723A (en) | 1989-05-31 | 1995-02-21 | Neorx Corporation | Oligonucleotide conjugates |
| US5254469A (en) | 1989-09-12 | 1993-10-19 | Eastman Kodak Company | Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures |
| US5486603A (en) | 1990-01-08 | 1996-01-23 | Gilead Sciences, Inc. | Oligonucleotide having enhanced binding affinity |
| US5608046A (en) | 1990-07-27 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Conjugated 4'-desmethyl nucleoside analog compounds |
| US5245022A (en) | 1990-08-03 | 1993-09-14 | Sterling Drug, Inc. | Exonuclease resistant terminally substituted oligonucleotides |
| US5512667A (en) | 1990-08-28 | 1996-04-30 | Reed; Michael W. | Trifunctional intermediates for preparing 3'-tailed oligonucleotides |
| CA2095212A1 (en) | 1990-11-08 | 1992-05-09 | Hybridon, Inc. | Incorporation of multiple reporter groups on synthetic oligonucleotides |
| RU2175657C2 (ru) * | 1990-11-08 | 2001-11-10 | Чирон Корпорейшн | Асиалогликопротеин вируса гепатита c (нсv), иммуногенная композиция, способ индукции иммунного ответа, способ иммуноанализа |
| ATE239484T1 (de) | 1991-10-24 | 2003-05-15 | Isis Pharmaceuticals Inc | Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen |
| NL9201440A (nl) | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennaire clusterglycosiden, hun bereiding en toepassing. |
| US5574142A (en) | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
| US5580731A (en) | 1994-08-25 | 1996-12-03 | Chiron Corporation | N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith |
| DE69527857T2 (de) | 1994-10-06 | 2003-05-28 | Buchardt, Dorte | Peptid-nukleinsäure-konjugate |
| US5684142A (en) | 1995-06-07 | 1997-11-04 | Oncor, Inc. | Modified nucleotides for nucleic acid labeling |
| JP2000501414A (ja) | 1995-11-22 | 2000-02-08 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 生体分子の細胞取り込みを高めるリガンド |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US5770716A (en) | 1997-04-10 | 1998-06-23 | The Perkin-Elmer Corporation | Substituted propargylethoxyamido nucleosides, oligonucleotides and methods for using same |
| IL132941A0 (en) | 1997-05-21 | 2001-03-19 | Univ Leland Stanford Junior | Composition and method for enhancing transport across biological membranes |
| DE69829760T3 (de) | 1997-09-12 | 2016-04-14 | Exiqon A/S | Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga |
| US6096875A (en) | 1998-05-29 | 2000-08-01 | The Perlein-Elmer Corporation | Nucleotide compounds including a rigid linker |
| US6300319B1 (en) | 1998-06-16 | 2001-10-09 | Isis Pharmaceuticals, Inc. | Targeted oligonucleotide conjugates |
| US6335432B1 (en) | 1998-08-07 | 2002-01-01 | Bio-Red Laboratories, Inc. | Structural analogs of amine bases and nucleosides |
| US6335437B1 (en) | 1998-09-07 | 2002-01-01 | Isis Pharmaceuticals, Inc. | Methods for the preparation of conjugated oligomers |
| KR100573231B1 (ko) | 1999-02-12 | 2006-04-24 | 상꾜 가부시키가이샤 | 신규 뉴클레오시드 및 올리고뉴클레오티드 유사체 |
| AU776362B2 (en) | 1999-05-04 | 2004-09-09 | Roche Innovation Center Copenhagen A/S | L-ribo-LNA analogues |
| US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
| WO2005007855A2 (en) | 2003-07-14 | 2005-01-27 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF B7-H1 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US20060276422A1 (en) | 2001-05-18 | 2006-12-07 | Nassim Usman | RNA interference mediated inhibition of B7-H1 gene expression using short interfering nucleic acid (siNA) |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| EP2206517B1 (en) * | 2002-07-03 | 2023-08-02 | Ono Pharmaceutical Co., Ltd. | Immunopotentiating compositions comprising anti-PD-L1 antibodies |
| EP2752488B1 (en) | 2002-11-18 | 2020-02-12 | Roche Innovation Center Copenhagen A/S | Antisense design |
| DK2270162T3 (en) | 2003-06-12 | 2019-01-21 | Alnylam Pharmaceuticals Inc | PRESERVED HBV AND HCV SEQUENCES USED FOR GEN-SILENCING |
| DK1495769T3 (da) | 2003-07-11 | 2008-06-23 | Lbr Medbiotech B V | Mannose-6-phosphat-receptormedieret gentransfer til muskelceller |
| CN101084438B (zh) * | 2004-10-06 | 2013-12-25 | 梅约医学教育与研究基金会 | B7-h1和癌症的诊断、预后和治疗方法 |
| WO2006042237A2 (en) | 2004-10-06 | 2006-04-20 | Mayo Foundation For Medical Education And Research | B7-h1 and methods of diagnosis, prognosis, and treatment of cancer |
| US20120122801A1 (en) | 2005-01-05 | 2012-05-17 | Prosensa B.V. | Mannose-6-phosphate receptor mediated gene transfer into muscle cells |
| CN104436190A (zh) | 2005-06-08 | 2015-03-25 | 达纳-法伯癌症研究院公司 | 通过抑制程序性细胞死亡1(pd-1)途经治疗持续性感染和癌症的方法及组合物 |
| WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
| CA2640171C (en) | 2006-01-27 | 2014-10-28 | Isis Pharmaceuticals, Inc. | 6-modified bicyclic nucleic acid analogs |
| CA3044969A1 (en) | 2006-05-05 | 2007-12-21 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating gene expression |
| JP5441688B2 (ja) | 2006-05-11 | 2014-03-12 | アイシス ファーマシューティカルズ， インコーポレーテッド | ５’修飾二環式核酸類似体 |
| US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
| CA2673870A1 (en) * | 2006-12-27 | 2008-07-10 | Emory University | Compositions and methods for the treatment of infections and tumors |
| US8580756B2 (en) | 2007-03-22 | 2013-11-12 | Santaris Pharma A/S | Short oligomer antagonist compounds for the modulation of target mRNA |
| EP2170917B1 (en) | 2007-05-30 | 2012-06-27 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
| ES2386492T3 (es) | 2007-06-08 | 2012-08-21 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos carbocíclicos |
| CN101796062B (zh) | 2007-07-05 | 2014-07-30 | Isis制药公司 | 6-双取代双环核酸类似物 |
| WO2009067647A1 (en) | 2007-11-21 | 2009-05-28 | Isis Pharmaceuticals, Inc. | Carbocyclic alpha-l-bicyclic nucleic acid analogs |
| WO2009090182A1 (en) | 2008-01-14 | 2009-07-23 | Santaris Pharma A/S | C4'-substituted - dna nucleotide gapmer oligonucleotides |
| WO2009124238A1 (en) | 2008-04-04 | 2009-10-08 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides |
| WO2009126933A2 (en) | 2008-04-11 | 2009-10-15 | Alnylam Pharmaceuticals, Inc. | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
| DK2356129T3 (da) | 2008-09-24 | 2013-05-13 | Isis Pharmaceuticals Inc | Substituerede alpha-L-bicykliske nukleosider |
| EP2370593B1 (en) | 2008-11-28 | 2016-03-30 | Emory University | Methods for determining the efficacy of pd-1 antagonists |
| HUE065752T2 (hu) * | 2008-12-09 | 2024-06-28 | Hoffmann La Roche | Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére |
| US9181525B2 (en) * | 2009-03-06 | 2015-11-10 | Mie University | Method for enhancing a function of a T cell |
| CN102459596B (zh) * | 2009-05-06 | 2016-09-07 | 库尔纳公司 | 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病 |
| WO2010138806A2 (en) * | 2009-05-28 | 2010-12-02 | Curna, Inc. | Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene |
| WO2011017521A2 (en) | 2009-08-06 | 2011-02-10 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
| AU2011237630B2 (en) * | 2010-04-06 | 2016-01-21 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of CD274/PD-L1 gene |
| WO2011143762A1 (en) * | 2010-05-18 | 2011-11-24 | The Royal Institution For The Advancement Of Learning / Mcgill University | Method for reducing expression of downregulated iν renal cell carcinoma iν malignant gliomas |
| EP2580228B1 (en) | 2010-06-08 | 2016-03-23 | Ionis Pharmaceuticals, Inc. | Substituted 2'-amino and 2'-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
| JP2013537423A (ja) | 2010-08-17 | 2013-10-03 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いたＢ型肝炎ウイルス（ＨＢＶ）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| PT3124610T (pt) | 2010-10-28 | 2019-06-14 | Benitec Biopharma Ltd | Tratamento do vhb |
| CA2816155C (en) | 2010-12-17 | 2020-10-27 | Arrowhead Research Corporation | Galactose cluster-pharmacokinetic modulator targeting moiety for sirna |
| CA2822161C (en) | 2010-12-29 | 2018-05-29 | Philipp Hadwiger | Small molecule conjugates for intracellular delivery of nucleic acids |
| MX347253B (es) | 2011-04-21 | 2017-04-20 | Ionis Pharmaceuticals Inc | Modulación de la expresión del virus de hepatitis b (vhb). |
| SG194751A1 (en) | 2011-06-30 | 2013-12-30 | Arrowhead Res Corp | Compositions and methods for inhibiting gene expression of hepatitis b virus |
| US9605019B2 (en) | 2011-07-19 | 2017-03-28 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
| US10023861B2 (en) | 2011-08-29 | 2018-07-17 | Ionis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
| CA2863253A1 (en) | 2011-09-07 | 2013-03-14 | Marina Biotech, Inc. | Synthesis and uses of nucleic acid compounds with conformationally restricted monomers |
| WO2013049307A2 (en) | 2011-09-30 | 2013-04-04 | University Of Miami | Enhanced immune memory development by aptamer targeted mtor inhibition of t cells |
| ES2918580T3 (es) * | 2011-10-17 | 2022-07-19 | Io Biotech Aps | Inmunoterapia basada en PD-L1 |
| EP2850092B1 (en) | 2012-04-09 | 2017-03-01 | Ionis Pharmaceuticals, Inc. | Tricyclic nucleic acid analogs |
| WO2013159109A1 (en) | 2012-04-20 | 2013-10-24 | Isis Pharmaceuticals, Inc. | Modulation of hepatitis b virus (hbv) expression |
| EP2850183A4 (en) | 2012-05-16 | 2016-02-10 | Rana Therapeutics Inc | COMPOSITIONS AND METHOD FOR MODULATING GENE EXPRESSION |
| BR112014028644A2 (pt) * | 2012-05-16 | 2017-08-15 | Rana Therapeutics Inc | Composições e métodos para modulação da expressão de atp2a2 |
| SG11201500239VA (en) | 2012-07-13 | 2015-03-30 | Wave Life Sciences Japan | Asymmetric auxiliary group |
| JP6452614B2 (ja) * | 2012-11-15 | 2019-01-16 | ロシュ イノベーション センター コペンハーゲン エーエス | オリゴヌクレオチドコンジュゲート |
| JP6998646B2 (ja) | 2012-11-30 | 2022-02-04 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｐｄ－ｌ１阻害剤併用療法を必要とする患者の同定 |
| WO2014118272A1 (en) * | 2013-01-30 | 2014-08-07 | Santaris Pharma A/S | Antimir-122 oligonucleotide carbohydrate conjugates |
| DK2951305T3 (en) * | 2013-01-30 | 2018-10-29 | Hoffmann La Roche | LNA oligonucleotide KULHYDRATKONJUGATER |
| PE20152002A1 (es) | 2013-05-01 | 2016-01-21 | Isis Pharmaceuticals Inc | Composiciones y metodos para modular la expresion de ttr y vhb |
| SG10201908122XA (en) | 2013-06-27 | 2019-10-30 | Roche Innovation Ct Copenhagen As | Antisense oligomers and conjugates targeting pcsk9 |
| EP3102697A1 (en) * | 2014-02-03 | 2016-12-14 | Myriad Genetics, Inc. | Method for predicting the response to an anti-her2 containing therapy and/or chemotherapy in patients with breast cancer |
| US20170216403A1 (en) | 2014-08-12 | 2017-08-03 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker |
| CN106795200B (zh) | 2014-10-10 | 2020-06-19 | 豪夫迈·罗氏有限公司 | Galnac亚磷酰胺、其核酸缀合物及其用途 |
| WO2016138278A2 (en) | 2015-02-27 | 2016-09-01 | Idera Pharmaceuticals, Inc. | Compositions for inhibiting checkpoint gene expression and uses thereof |
| GB201507926D0 (en) * | 2015-05-08 | 2015-06-24 | Proqr Therapeutics N V | Improved treatments using oligonucleotides |
| EP3355932B1 (en) * | 2015-10-02 | 2023-04-12 | Roche Innovation Center Copenhagen A/S | Oligonucleotide conjugation process |
| AR106683A1 (es) | 2015-11-16 | 2018-02-07 | Hoffmann La Roche | FOSFORAMIDITA DE AGRUPACIÓN DE GalNAc |
| US10982215B2 (en) | 2015-12-09 | 2021-04-20 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting programmed cell death 1 ligand 1 (PD-L1) and methods of use thereof |
| TWI840950B (zh) | 2016-03-14 | 2024-05-01 | 瑞士商赫孚孟拉羅股份公司 | 用於降低pd-l1表現之寡核苷酸 |
| WO2018215049A1 (en) | 2017-05-23 | 2018-11-29 | F. Hoffmann-La Roche Ag | Process for galnac oligonucleotide conjugates |
-
2017
- 2017-03-14 TW TW111134997A patent/TWI840950B/zh active
- 2017-03-14 US US15/458,800 patent/US20170283496A1/en not_active Abandoned
- 2017-03-14 PT PT177108743T patent/PT3430141T/pt unknown
- 2017-03-14 EP EP17710874.3A patent/EP3430141B1/en active Active
- 2017-03-14 IL IL303077A patent/IL303077B2/en unknown
- 2017-03-14 KR KR1020227022628A patent/KR102580776B1/ko active Active
- 2017-03-14 MY MYPI2018703228A patent/MY194912A/en unknown
- 2017-03-14 CR CR20180432A patent/CR20180432A/es unknown
- 2017-03-14 SG SG11201807854SA patent/SG11201807854SA/en unknown
- 2017-03-14 KR KR1020257014623A patent/KR20250065735A/ko active Pending
- 2017-03-14 PL PL17710874T patent/PL3430141T3/pl unknown
- 2017-03-14 TW TW106108305A patent/TWI721128B/zh active
- 2017-03-14 PE PE2018001567A patent/PE20181892A1/es unknown
- 2017-03-14 MX MX2018010830A patent/MX2018010830A/es unknown
- 2017-03-14 DK DK17710874.3T patent/DK3430141T3/da active
- 2017-03-14 CN CN202210440723.8A patent/CN114717235A/zh active Pending
- 2017-03-14 CN CN202210443059.2A patent/CN114736901B/zh active Active
- 2017-03-14 CN CN202210442730.1A patent/CN114736900B/zh active Active
- 2017-03-14 RS RS20210240A patent/RS61528B1/sr unknown
- 2017-03-14 EP EP20201780.2A patent/EP3786297A1/en active Pending
- 2017-03-14 IL IL317818A patent/IL317818A/en unknown
- 2017-03-14 TW TW109135755A patent/TWI790485B/zh active
- 2017-03-14 CN CN202111366505.6A patent/CN114085836B/zh active Active
- 2017-03-14 KR KR1020217030513A patent/KR102417646B1/ko active Active
- 2017-03-14 IL IL296483A patent/IL296483B2/en unknown
- 2017-03-14 SI SI201730645T patent/SI3430141T1/sl unknown
- 2017-03-14 UA UAA201810179A patent/UA127432C2/uk unknown
- 2017-03-14 LT LTEP17710874.3T patent/LT3430141T/lt unknown
- 2017-03-14 TW TW109135754A patent/TWI794662B/zh active
- 2017-03-14 PE PE2020000807A patent/PE20201499A1/es unknown
- 2017-03-14 CA CA3120687A patent/CA3120687A1/en active Pending
- 2017-03-14 HR HRP20210315TT patent/HRP20210315T1/hr unknown
- 2017-03-14 PE PE2022000852A patent/PE20230157A1/es unknown
- 2017-03-14 AU AU2017235278A patent/AU2017235278C1/en active Active
- 2017-03-14 ES ES17710874T patent/ES2857702T3/es active Active
- 2017-03-14 HU HUE17710874A patent/HUE053172T2/hu unknown
- 2017-03-14 CN CN201780017220.7A patent/CN108779465B/zh active Active
- 2017-03-14 RU RU2018134379A patent/RU2747822C2/ru active
- 2017-03-14 TW TW113111556A patent/TW202428874A/zh unknown
- 2017-03-14 AR ARP170100626A patent/AR108038A1/es unknown
- 2017-03-14 CR CR20200119A patent/CR20200119A/es unknown
- 2017-03-14 JP JP2018548393A patent/JP6748219B2/ja active Active
- 2017-03-14 CA CA3013683A patent/CA3013683C/en active Active
- 2017-03-14 KR KR1020237031671A patent/KR102805002B1/ko active Active
- 2017-03-14 KR KR1020187026546A patent/KR102306797B1/ko active Active
- 2017-03-14 WO PCT/EP2017/055925 patent/WO2017157899A1/en not_active Ceased
-
2018
- 2018-07-24 IL IL260759A patent/IL260759B/en unknown
- 2018-07-26 CO CONC2018/0007761A patent/CO2018007761A2/es unknown
- 2018-09-07 MX MX2022012221A patent/MX2022012221A/es unknown
- 2018-09-07 CL CL2018002570A patent/CL2018002570A1/es unknown
- 2018-09-12 PH PH12018501964A patent/PH12018501964A1/en unknown
-
2019
- 2019-10-25 US US16/664,749 patent/US10745480B2/en active Active
-
2020
- 2020-03-31 CL CL2020000865A patent/CL2020000865A1/es unknown
- 2020-04-02 US US16/839,025 patent/US10829555B2/en active Active
- 2020-04-17 AR ARP200101090A patent/AR118719A2/es unknown
- 2020-04-28 CL CL2020001127A patent/CL2020001127A1/es unknown
- 2020-04-28 CL CL2020001126A patent/CL2020001126A1/es unknown
- 2020-06-22 JP JP2020106728A patent/JP7002603B2/ja active Active
- 2020-08-21 US US17/000,203 patent/US11466081B2/en active Active
-
2021
- 2021-09-20 AU AU2021236439A patent/AU2021236439B2/en active Active
- 2021-12-27 JP JP2021212541A patent/JP7447073B2/ja active Active
-
2022
- 2022-02-01 IL IL290294A patent/IL290294B2/en unknown
- 2022-04-13 AU AU2022202479A patent/AU2022202479B2/en active Active
- 2022-10-07 US US18/045,109 patent/US12552862B2/en active Active
-
2024
- 2024-01-04 JP JP2024000251A patent/JP7791222B2/ja active Active
- 2024-05-29 AU AU2024203581A patent/AU2024203581A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019512498A5 (enExample) | ||
| JP2021072862A5 (enExample) | ||
| IL317818A (en) | Oligonucleotides to reduce PD-L1 expression | |
| Martinsen et al. | The use of toll-like receptor agonists in HIV-1 cure strategies | |
| JP2020022483A5 (enExample) | ||
| JP2017505623A5 (enExample) | ||
| US9415113B2 (en) | Targeting monomers and polymers having targeting blocks | |
| KR101764427B1 (ko) | 미셀성 어셈블리 | |
| US9943604B2 (en) | Targeted therapeutic nucleosides and their use | |
| JP6649248B2 (ja) | 細胞取り込みの向上のための化合物および方法 | |
| CN102272179B (zh) | 多嵌段共聚物 | |
| KR102627418B1 (ko) | 변형된 올리고뉴클레오티드 및 사용 방법 | |
| US20180230464A1 (en) | Chemically Ligated RNAs for CRISPR/Cas9-lgRNA Complexes as Antiviral Therapeutic Agents | |
| US20200270609A1 (en) | Single-Stranded RNAI Oligonucleotides Targeting APOC-III | |
| IL300119A (en) | Oligonucleotides to induce paternal UBE3A expression | |
| HRP20250408T1 (hr) | Kojugati i njihova priprema i uporaba | |
| HRP20250974T1 (hr) | Oligomeri i oligomerni konjugati | |
| JP2010532168A5 (enExample) | ||
| JP2021500025A5 (enExample) | ||
| RU2017139121A (ru) | Композиции для модулирования экспрессии c9orf72 | |
| JP2017513469A5 (enExample) | ||
| TW201639962A (zh) | Ｒｎａ干擾劑 | |
| MX2010012236A (es) | Portador polimerico. | |
| JP2009524696A5 (enExample) | ||
| WO2009140423A2 (en) | Targeted polymer bioconjugates |